These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18267331)

  • 1. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
    Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    BJU Int; 2008 Apr; 101(7):817-21. PubMed ID: 18321315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL; Chen MH; Renshaw AA; Sussman B; D'Amico AV
    Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Kumar A; Godoy G; Taneja SS
    Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
    Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
    Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
    Bohnen AM; Groeneveld FP; Bosch JL
    Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
    Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
    Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receiver operating characteristics of the prostate specific antigen test in an unselected population.
    McLernon DJ; Donnan PT; Gray M; Weller D; Sullivan F
    J Med Screen; 2006; 13(2):102-7. PubMed ID: 16792835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.